SEARCH

SEARCH BY CITATION

References

  • 1
    Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680689.
  • 2
    WHO. Pandemic (H1N1) 2009 – update 87. Available at http://www.who.int/csr/don/2010_02_12/en/index.html (Accessed 18 February 2010).
  • 3
    Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:13331340.
  • 4
    Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179186.
  • 5
    Choi WJ, Kim WY, Kim SH et al. Clinical characteristics of pneumonia in hospitalized patients with novel influenza A (H1N1) in Korea. Scand J Infect Dis 2010; 42:311314.
  • 6
    Choi SS, Kim WY, Kim SH et al. Associated factor related to major complications of patients with hospitalized for 2009 H1N1 influenza pneumonia. Tuberc Respir Dis 2010; 68:162167.
  • 7
    Brundage JF, Shanks GD. Deaths from bacterial pneumonia during 1918–19 influenza pandemic. Emerg Infect Dis 2008; 14:11931199.
  • 8
    Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962970.
  • 9
    Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341:515518.
  • 10
    Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600607.
  • 11
    Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COFD – a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:919.
  • 12
    Guervilly C, Coisel Y, Botelho-Nevers E et al. Significance of high levels of procalcitonin in patients with influenza A (H1N1) pneumonia. J Infect 2010; 61:355358.
  • 13
    Ingram PR, Inglis T, Moxon D, Speers D. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med 2010; 36:528532.
  • 14
    Piacentini E, Sanchez B, Arauzo V, Calbo E, Cuchi E, Nava JM. Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot study. J Crit Care 2010; [Epub ahead of print].
  • 15
    Duncan C, Guthrie JL, Tijet N et al. Analytical and clinical validation of novel real-time reverse transcriptase-polymerase chain reaction assays for the clinical detection of swine-origin H1N1 influenza viruses. Diagn Microbiol Infect Dis 2011; 69:167171.
  • 16
    Soler N, Torres A, Ewig S et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157:14981505.
  • 17
    Murata Y, Walsh EE, Falsey AR. Pulmonary complications of interpandemic influenza A in hospitalized adults. J Infect Dis 2007; 195:10291037.
  • 18
    McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571.
  • 19
    Chirouze C, Schuhmacher H, Rabaud C et al. Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis 2002; 35:156161.
  • 20
    Chua AP, Lee KH. Procalcitonin in severe acute respiratory syndrome (SARS). J Infect 2004; 48:303306.
  • 21
    Toikka P, Irjala K, Juven T et al. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 2000; 19:598602.
  • 22
    Lacour AG, Gervaix A, Zamora SA et al. Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr 2001; 160:95100.
  • 23
    Moulin F, Raymond J, Lorrot M et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001; 84:332336.
  • 24
    Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206217.
  • 25
    Wright PF, Kirkland KB, Modlin JF. When to consider the use of antibiotics in the treatment of 2009 H1N1 influenza-associated pneumonia. N Engl J Med 2009; 361:e112.
  • 26
    Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006; 32:469472.
  • 27
    Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia a randomized trial. Am J Respir Crit Care Med 2006; 174:8493.